Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen
- PMID: 14624369
- DOI: 10.1086/379041
Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen
Abstract
We compared immune restoration in patients who suppressed human immunodeficiency virus type 1 replication after treatment with a protease inhibitor (PI) plus nevirapine or with 3 nucleoside reverse-transcriptase inhibitors (NRTIs) plus nevirapine. Changes in total and memory CD4 and CD8 cells were similar in the groups, as were decreases in immune activation (e.g., CD38 and HLA-DR) and increases in CD28 expression. Increases in naive CD4 and CD8 cells tended to be greater in the NRTI-treated group, with differences in naive CD4 cells significant at weeks 8 and 12 (P<.05) but not at week 48. Lymphocyte apoptosis decreased in both groups, but the week-1 decrease was greater in the PI-treated group (P<.02). Lymphocyte proliferation and skin-test responses were comparable. We find little evidence for differences in the major direct immunologic effect of PI versus NRTI regimens and propose that effects observed elsewhere were indirect, mediated through antiviral activity or adaptation of the virus to selection pressure.
Similar articles
-
Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.Antivir Ther. 2004 Apr;9(2):197-204. Antivir Ther. 2004. PMID: 15134181 Clinical Trial.
-
Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children.J Infect Dis. 2000 Jul;182(1):96-103. doi: 10.1086/315672. Epub 2000 Jun 27. J Infect Dis. 2000. PMID: 10882586 Clinical Trial.
-
Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.AIDS. 2009 Apr 27;23(7):817-24. doi: 10.1097/QAD.0b013e328328f789. AIDS. 2009. PMID: 19363330 Clinical Trial.
-
An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.AIDS. 2006 Oct 24;20(16):2051-64. doi: 10.1097/01.aids.0000247578.08449.ff. AIDS. 2006. PMID: 17053351 Review.
-
[Nevirapine (Viramune): a new HIV inhibitor].Rev Med Brux. 1999 Apr;20(2):95-9. Rev Med Brux. 1999. PMID: 10335104 Review. French.
Cited by
-
Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV.J Acquir Immune Defic Syndr. 2010 May 1;54(1):59-62. doi: 10.1097/QAI.0b013e3181c96520. J Acquir Immune Defic Syndr. 2010. PMID: 20182359 Free PMC article.
-
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.AIDS. 2012 Jul 17;26(11):1371-85. doi: 10.1097/QAD.0b013e328354f4fb. AIDS. 2012. PMID: 22546988 Free PMC article. Clinical Trial.
-
No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.Clin Infect Dis. 2011 Apr 1;52(7):929-40. doi: 10.1093/cid/ciq244. Clin Infect Dis. 2011. PMID: 21427402 Free PMC article. Clinical Trial.
-
AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics.HIV Clin Trials. 2008 Jul-Aug;9(4):269-82. doi: 10.1310/hct0904-269. HIV Clin Trials. 2008. PMID: 18753121 Free PMC article.
-
Intracellular Casp8p41 content is inversely associated with CD4 T cell count.J Infect Dis. 2010 Aug 15;202(3):386-91. doi: 10.1086/653705. J Infect Dis. 2010. PMID: 20565257 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous